Zealand Pharma A/S (ZEAL) — Working Capital to Net Assets Ratio
Zealand Pharma A/S (ZEAL) has a Working Capital to Net Assets ratio of 101.2% as of December 2025. Working capital of Dkr15.01 Billion (current assets of Dkr15.67 Billion minus current liabilities of Dkr664.97 Million) is measured against net assets of Dkr14.83 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Zealand Pharma A/S free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zealand Pharma A/S Working Capital to Net Assets (2007–2025)
This chart shows how Zealand Pharma A/S's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of December 2025, the ratio stands at 101.2%, reflecting working capital of Dkr15.01 Billion against net assets of Dkr14.83 Billion DKK. See defensive interval ratio of Zealand Pharma A/S to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zealand Pharma A/S (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zealand Pharma A/S from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Zealand Pharma A/S (ZEAL) market capitalisation.
| Year | WC/NA Ratio | Working Capital (DKK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 101.2% | Dkr15.01 Billion | Dkr14.83 Billion | Dkr15.67 Billion | Dkr664.97 Million | ▲ +6.9 pp |
| 2024 | 94.3% | Dkr8.12 Billion | Dkr8.62 Billion | Dkr8.53 Billion | Dkr403.47 Million | ▲ +0.4 pp |
| 2023 | 93.9% | Dkr1.50 Billion | Dkr1.59 Billion | Dkr1.78 Billion | Dkr284.58 Million | ▼ -43.5 pp |
| 2022 | 137.4% | Dkr1.12 Billion | Dkr815.91 Million | Dkr1.32 Billion | Dkr195.49 Million | ▼ -12.1 pp |
| 2021 | 149.5% | Dkr1.39 Billion | Dkr927.80 Million | Dkr1.72 Billion | Dkr334.32 Million | ▲ +92.8 pp |
| 2020 | 56.7% | Dkr667.30 Million | Dkr1.18 Billion | Dkr1.25 Billion | Dkr577.73 Million | ▼ -42.4 pp |
| 2019 | 99.1% | Dkr1.23 Billion | Dkr1.24 Billion | Dkr1.43 Billion | Dkr195.13 Million | ▲ +3.7 pp |
| 2018 | 95.4% | Dkr1.07 Billion | Dkr1.12 Billion | Dkr1.18 Billion | Dkr113.52 Million | ▼ -23.3 pp |
| 2017 | 118.7% | Dkr627.41 Million | Dkr528.47 Million | Dkr703.19 Million | Dkr75.78 Million | ▲ +16.1 pp |
| 2016 | 102.7% | Dkr285.62 Million | Dkr278.19 Million | Dkr373.17 Million | Dkr87.55 Million | ▼ -113.8 pp |
| 2015 | 216.5% | Dkr546.06 Million | Dkr252.23 Million | Dkr615.57 Million | Dkr69.51 Million | ▲ +19.3 pp |
| 2014 | 197.2% | Dkr498.68 Million | Dkr252.83 Million | Dkr575.44 Million | Dkr76.76 Million | ▲ +104.4 pp |
| 2013 | 92.8% | Dkr293.51 Million | Dkr316.14 Million | Dkr324.28 Million | Dkr30.77 Million | ▼ -2.0 pp |
| 2012 | 94.8% | Dkr465.56 Million | Dkr491.01 Million | Dkr496.95 Million | Dkr31.39 Million | ▼ -0.6 pp |
| 2011 | 95.4% | Dkr421.03 Million | Dkr441.40 Million | Dkr449.11 Million | Dkr28.08 Million | ▼ -1.4 pp |
| 2010 | 96.8% | Dkr394.14 Million | Dkr407.11 Million | Dkr437.58 Million | Dkr43.44 Million | ▲ +5.9 pp |
| 2009 | 91.0% | Dkr120.91 Million | Dkr132.92 Million | Dkr146.66 Million | Dkr25.75 Million | ▼ -3.2 pp |
| 2008 | 94.2% | Dkr196.55 Million | Dkr208.63 Million | Dkr213.16 Million | Dkr16.61 Million | ▼ -1.3 pp |
| 2007 | 95.6% | Dkr231.59 Million | Dkr242.37 Million | Dkr251.47 Million | Dkr19.88 Million | — |